1) 清水敬生 : 病理組織型を考慮した化学療法.産婦治療88 : 35─45,2004
2) 石倉 浩,手島伸一(編) : 卵巣腫瘍病理アトラス.文光堂,2004
3) 三上芳喜 : 漿液性境界悪性腫瘍の形態と漿液性腺癌との鑑別.病理と臨24 : 146─153,2006
4) Ho CL, Kurman, RJ, Dehari R, et al : Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors. Cancer Res 64 : 6915─6918,2004
5) Bell DA : Origins and molecular pathology of ovarian cancer. Modern Pathology 18 : 19─32,2005
6) 井上正樹 : 卵巣腫瘍─初期腺癌(診断編)I.産婦治療89 : 353─361,2004
7) Dehari R, Kurman RJ, Logani S, et al : The development of high-grade serous carcinoma from atypical proliferative(borderline)serous tumors and low-grade micropapillary serous carcinoma. Am J Surg Pathol 31 : 1007─1012,2007
8) Parker RL, Clement PB, Chercover DJ, et al : Early recurrence of ovarian serous borderline tumors as high-grade carcinoma : a report of two cases. Int J Gynecol Pathol 23 : 265─272,2004
9) Pal T, Wey JP, Betts JA, et al : BRCA 1 and BRCA 2 mutations account for a large proportion of ovarian carcinoma cases. Cancer 104 : 2807─2816,2005
10) 榎本隆之,藤田征巳,村田雄二 : 卵巣癌の分子生物学─癌遺伝子,癌抑制遺伝子.産と婦66 : 18─25,1999
11) Köbel M, Kalloger SE, Boyd N, et al : Ovarian carcinoma subtypes are different diseases : implications for biomarker studies. PLoS Med 5 : 1749─1760, 2008
12) 小畑孝四郎,小池英爾,椎名昌美 : 卵巣子宮内膜症の悪性化.病理と臨24 : 249─255,2006